Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-α generation

British Journal of Pharmacology

Volumn 122, Issue 1, 1997, Pages 149-157

  Meja, Koremu K ^a   Barnes, Peter J ^a   Giembycz, Mark A ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Butaprost; Cicaprost; EP2 receptors; EP4 receptors; Human monocytes; IP receptors; TNF generation

Indexed keywords

11 DEOXY 16 PHENOXY 17,18,19,20 TETRANORPROSTAGLANDIN E1; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 16,16 DIMETHYLPROSTAGLANDIN E2; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; BUTAPROST; CELL RECEPTOR; CICAPROST; LIPOPOLYSACCHARIDE; MISOPROSTOL; PARTIAL AGONIST; PROSTACYCLIN; PROSTAGLANDIN D; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; SULPROSTONE; THROMBOXANE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ADHESION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MONOCYTE; PRIORITY JOURNAL; RECEPTOR AFFINITY;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; BIPHENYL COMPOUNDS; DINOPROSTONE; DRUG INTERACTIONS; EPOPROSTENOL; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; PROSTAGLANDIN ANTAGONISTS; PROSTAGLANDIN ENDOPEROXIDES, SYNTHETIC; PROSTANOIC ACIDS; RECEPTORS, PROSTAGLANDIN; THROMBOXANE A2; TUMOR NECROSIS FACTOR-ALPHA; XANTHENES; XANTHONES;

EID: 0030776485     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701360     Document Type: Article

References (64)

1. ABRAMOVITZ, M., BOIE, Y., NGUYEN, T., RUSHMORE, T.H., BAYNE, M.A., METTERS, K.M., SLIPETZ, D.M. & GRYGORCZYK, R. (1994). Cloning and expression of a cDNA for the human prostanoid FP receptor. J. Biol. Chem., 269, 2632-2636.
2. 2 receptor transduce both intracellular calcium and cyclic AMP signals. Biochemistry, 33, 14496-14502.
3. ARMSTRONG, R.A., JONES, N.L. & WILSON, N.L. (1983). Ligand binding to thromboxane receptors on human platelets: correlation with biological activity. Br. J. Pharmacol., 79, 953-964.
4. 2 subtype. J. Biol. Chem., 269, 11873-11877.
5. 2 receptor subtype 4 mRNA in human mononuclear Jurkat and KM-3 cells and coexpression of subtype 4 and 2 mRNA in U-937 cells. FEBS Letts., 394, 39-43.
6. BOIE, Y., RUSHMORE, T.H., DARMON-GOODWIN, A., GRYGORCZYK., R., SLIPETZ, D.M., METTERS, K.M. & ABRAMOVITZ, M. (1994). Cloning and expression of a cDNA for the human prostanoid IP receptor. J. Biol. Chem., 269, 12173-12178.
7. BOIE, Y., SAWYER, N., SLIPETZ, D.M., METTERS, K.M. & ABRAMOVITZ, M. (1995). Molecular cloning and characterization of the human prostanoid DP-receptor. J. Biol. Chem., 270, 18910-18916.
8. BROWN, C.J., BOERSMA, J.I. & CRANKSHAW, D.J. (1997). Effect of AH6809 on prostanoid-induced relaxation of human myometrium in vitro. Br. J. Pharmacol., 120, 338P.
9. 1-receptor blocking drug, AH 6809. Br. J. Pharmacol., 86, 803P.
10. COLEMAN, R.A., GRIX, S.P., HEAD, S.A., LOUTTIT, J.B., MALLETT, A. & SHELDRICK, R.L.G. (1994a). A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins, 47, 151-168.
11. COLEMAN, R.A., HUMPHREY, P.P.A., KENNEDY, I. & LUMLEY, P. (1984). Prostanoid receptors - the development of a working classification. Trends. Pharmacol. Sci., 5, 303-306.
12. COLEMAN, R.A., HUMPHREY, P.P.A., SHELDRICK, R.L.G. & WHITE, B.P. (1988). Gastric antisecretory prostanoids: actions at different prostanoid receptors. Br. J. Pharmacol., 95, 724P.
13. 2-sensitive (EP) receptors. Adv. Prostaglandin Thromboxane Leukotriene Res., 17, 467-470.
14. COLEMAN, R.A., SMITH, W.L. & NURUMIYA, S. (1994b). International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev., 46, 205-229.
15. CRUTCHLEY, D.J., CONANAN, L.B. & QUE, B.G. (1994). Effect of prostacyclin analogs on the synthesis of tissue factor, tumor necrosis factor-α and interleukin-1β in human monocytic THP-1 cells. J. Pharmacol. Exp. Ther., 271, 446-451.
16. DE VRIES, G.W., GUARINO, P., MCLAGHLIN, A., CHEN, J., ANDREWS, S. & WOODWARD, D.F. (1995). An EP receptor with a novel pharmacological profile in the T-cell line Jurkat. Br. J. Pharmacol., 115, 1231-1234.
17. DONG, Y.J., JONES, R.L. & WILSON, N.M. (1986). Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues. Br. J. Pharmacol., 87, 97-107.
18. EISENHUT, T., SINHA, B., GRÖTTRUP-WOLFERS, E., SEMMLER, J., SIESS, W. & ENDRES, S. (1993). Prostacyclin analogs suppress the synthesis of tumor necrosis factor-α in LPS-stimulated human peripheral blood mononucleur cells. Immunopharmacology, 26, 259-264.
19. 2 receptors on human peripheral blood monocytes. Scand. J. Immunol., 21, 167-172.
20. 4. Mol. Immunol., 33, 33-45.
21. 1 receptor. J. Biol. Chem., 268, 26767-26772.
22. GARDINER, P. (1986). Characterisation of prostanoid relaxant/ inhibitory receptors (ψ) using a highly selective agonist, TR4979. Br. J. Pharmacol., 87, 45-56.
23. GRETEN, T.F., SINHA, B., HASLBERGER, C., EIGLER, A. & ENDRES, S. (1996). Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-α synthesis. Eur. J. Pharmacol., 299, 229-233.
24. 2 receptor. Nature, 349, 617-629.
25. HIRST, S.J., BARNES, P.J. & TWORT, C.H.C. (1992). Quantifying proliferation of cultured human and rabbit airway smooth muscle cells in response to serum and platelet-derived growth factor. Am. J. Respir. Cell. Mol. Biol., 7, 574-581.
26. 2 subtype. J. Biol. Chem., 268, 7759-7762.
27. HUMBLES, A.A., NIALS, A.T. & COLEMAN, R.A. (1991). Pharmacological characterisation of the prostanoid receptors in the rabbit isolated ear artery. Br. J. Pharmacol., 104, 418P.
28. 2. Biochem. Biophys. Res. Commun., 198, 999-1006.
29. JONES, R.L., WILSON, N.H. & ARMSTRONG, R.A. (1985). Characterisation of thromboxane receptors on human platelets. Adv. Exp. Med. Biol., 192, 67-81.
30. KEERY, R.J. & LUMLEY, P. (1988). AH 6809, a prostaglandin DP-receptor blocking drug on human platelets. Br. J. Pharmacol., 94, 745-754.
31. KENAKIN, T.P. (1987). Pharmacologic Analysis of Drug-Receptor Interaction. New York: Raven Press.
32. KENNEDY, I., COLEMAN, R.A., HUMPHREY, P.P.A., LEVY, G.P. & LUMLEY, P. (1982). Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins, 24, 667-689.
33. 3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol. Pharmacol., 48, 869-879.
34. 3-subtype from human erythroleukemia cells. Biochem. J., 298, 263-267.
35. LAWRENCE, R.A., JONES, R.L. & WILSON, N.H. (1991). Characterization of the receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum. Br. J. Pharmacol., 105, 271-278.
36. LAWRENCE, R.A. & JONES, R.L. (1992). Investigation of the prostaglandin E (EP-) receptor subtype mediating relaxation of the rabbit jugular vein. Br. J. Pharmacol., 105, 817-824.
37. 2 receptors expressed on human monocytic leukaemic cell line, U937. Biochim. Biophys. Acta. 1177, 43-48.
38. 2-sensitive (EP)-receptor in the rat isolated trachea. Br. J. Pharmacol., 112, 133-136.
39. LYDFORD, S.J., MCKECHNIE, K.C.W. & DOUGALL, I.G. (1996). Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit ear artery. Br. J. Pharmacol., 117, 13-20.
40. 3 subtype. Br. J. Pharmacol., 102, 573-576.
41. MEJA, K., SELDON, P.M., BARNES, P.J. & GIEMBYCZ, M.A. (1996). Characterisation of the prostanoid receptors that mediates inhibition of lipopolysaccharide-induced tumour necrosis factor-α generation from human monocytes. Br. J. Pharmacol., 119, 158P.
42. MILNE, S.A., ARMSTRONG, R.A. & WOODWARD, D.E. (1995). Comparison of the EP receptor subtypes mediating relaxation of the rabbit jugular and pig saphenous veins. Prostaglandins, 49, 225-237.
43. 4 receptors positively coupled to adenylyl cyclase. Br. J. Pharmacol., 113, 8P.
44. 3- and DP-receptors. Br. J. Pharmacol., 111, 733-738.
45. 3 determines G-protein specificity. Nature, 365, 166-170.
46. 2-agonist. Cardiovasc. Drug. Rev., 11, 165-179.
47. 4 subtype. FEBS Letts., 364, 339-341.
48. PRABHAKAR, U., LIPSHUTZ, D., O'LEARY-BARTUS, J., SLIVJAK, M.J., SMITH, E.F., LEE, J.C. & ESSER, K.M. (1994). Characterization of cyclic AMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase inhibitor. Int. J. Immunopharmacol., 16, 805-816.
49. 3-receptor agonists on human isolated pulmonary artery. Br. J. Pharmacol., 113, 369-374.
50. 3 receptors: evidence for three variants with different carboxy terminal. Br. J. Pharmacol., 112, 377-385.
51. 2-subtype. Mol. Pharmacol., 46, 213-220.
52. SELDON, P.M., BARNES, P.J., MEJA, K. & GIEMBYCZ, M.A. (1995). Suppression of lipopolysaccharide-induced tumor necrosis factor-α generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol. Pharmacol., 48, 747-757.
53. SEVERN, A., RAPSON, N.T., HUNTER, C.A. & LIEW, F.Y. (1992). Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J. Immunol., 148, 3441-3445.
54. SINHA, B., SEMMLER, J., EISENHUT, T., EIGLER, A. & ENDRES, S. (1995). Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur. J. Immunol., 25, 147-153.
55. SONNENBURG, W.K. & SMITH, W.L. (1988). Regulation of cyclic AMP metabolism in rabbit cortical collecting tubule cells by prostaglandins. J. Biol. Chem., 263, 6155-6160.
56. 3 receptors. Prostaglandins, 43, 559-566.
57. STURZENBECHNER, S., HABEREY, M., MULLER, B., SCHILLINGER, E., SCHRÖDER, G., SKUBALLA, W., STOCK, G., VORBRUGGEN, H. & WITT, W. (1986). Pharmacological profile of a new carbacyclin derivative with high metabolic stability and oral activity in the rat. Prostaglandins, 31, 95-109.
58. TAFFET, S.M., SINGHEL, K.J., OVERHOLTZER, J.F. & SHURTLEFF, S.A. (1990). Regulation of tumor necrosis factor expression in a macrophage-like cell line by lipopolysaccharide and cyclic AMP. Cell. Immunol., 155, 1230-1236.
59. TEIXEIRA, M.M., AL-RASHED, S., ROSSI, A.G. & HELLEWELL, P.G. (1997). Characterization of the prostanoid receptors mediating inhibition of PAF-induced aggregation of guinea-pig eosinophils. Br. J. Pharmacol., 121, 77-82.
60. 1 subtype of prostaglandin E receptor. J. Biol. Chem., 268, 21075-21078.
61. WISE, H. & JONES, R.L. (1994). Characterization of prostanoid receptors on rat neutrophils. Br. J. Pharmacol., 113, 581-587.
62. WISE, H. & JONES, R.L. (1996). Hocus on prostacyclin and its novel mimetics. Trends Pharmacol. Sci., 17, 17-21.
63. 2-receptor antagonist. Biochem. Pharmacol., 50, 1731-1733.
64. 2 receptors on U937 human monocytic cells. Immunology, 86, 620-628.